Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: Tupulak who wrote (31)	3/24/1999 10:36:00 PM
From: Tupulak	Respond to of 164

CALGARY, ALBERTA--(BUSINESS WIRE)--March 23, 1999-- SYNSORB(NASDAQ:SYBBF - news; TSE:SYB. - news) SYNSORB Biotech Inc. (''SYNSORB'') (TSE:SYB, NASDAQ: SYBBF) announced today that it has filed a preliminary short form prospectus with the securities commissions in Ontario, Quebec, Manitoba, Alberta and British Columbia relating to a proposed offering of common shares. The underwriting syndicate for the offering will be led by TD Securities Inc., and include HSBC James Capel Canada Inc., Canaccord Capital Corporation, Dundee Securities Corporation, and Loewen, Ondaatje, McCutcheon Limited. Net proceeds of the offering will be used primarily for operation of the manufacturing facility, clinical trials relating to SYNSORB Pk® and SYNSORB Cd®, other research and development expenses and for general corporate purposes. SYNSORB currently has 20,128,186 shares issued and outstanding. SYNSORB is dedicated to accelerated drug development from the acquisition of promising compounds emerging from basic research through clinical development, and ultimately to providing channels to market for new discoveries. Headquartered in Calgary, SYNSORB currently has two products in late stage clinical trials, SYNSORB Pk® for the treatment of verotoxigenic E. coli (VTEC) infections (including O157:H7), and SYNSORB Cd® designed to treat recurrent antibiotic-associated diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical development, including potential cancer treatments and novel antibiotics, with inflammation and anti-virals targeted in the Company's research and development program. This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. The common shares have not been and will not be registered under the United States Securities Act of 1993, as amended (the ''1933 Act''), and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons except in certain transactions exempt from the registration requirements of the 1933 Act. Contact: SYNSORB Biotech Inc. Doug Ball, 403/283-5900 403/283-5907 (Fax) synsorb.com or The Equicom Group Jason Hogan, 416/815-0700, ext. 222 416/815-0080 (Fax) United States: 800/385-5451 or SYNSORB Biotech Inc. Doug Froom, 403/283-5900 403/283-5907 (Fax)